Apellis Pharmaceuticals (NASDAQ:APLS) Insider Nur Nicholson Sells 2,618 Shares

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) insider Nur Nicholson sold 2,618 shares of the firm’s stock in a transaction on Tuesday, January 13th. The stock was sold at an average price of $22.19, for a total value of $58,093.42. Following the sale, the insider directly owned 81,046 shares of the company’s stock, valued at approximately $1,798,410.74. This represents a 3.13% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Apellis Pharmaceuticals Trading Up 1.0%

Shares of NASDAQ APLS opened at $20.53 on Friday. The company has a quick ratio of 3.10, a current ratio of 3.54 and a debt-to-equity ratio of 0.90. Apellis Pharmaceuticals, Inc. has a 12 month low of $16.10 and a 12 month high of $31.17. The company has a market cap of $2.60 billion, a price-to-earnings ratio of 66.23 and a beta of 0.31. The business has a fifty day simple moving average of $22.88 and a 200-day simple moving average of $23.39.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its quarterly earnings data on Thursday, October 30th. The company reported $1.67 EPS for the quarter, beating analysts’ consensus estimates of $1.03 by $0.64. The company had revenue of $458.58 million during the quarter, compared to analyst estimates of $364.58 million. Apellis Pharmaceuticals had a net margin of 4.43% and a return on equity of 18.94%. The business’s quarterly revenue was up 133.0% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.46) earnings per share. Sell-side analysts predict that Apellis Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

More Apellis Pharmaceuticals News

Here are the key news stories impacting Apellis Pharmaceuticals this week:

• Positive Sentiment: Wells Fargo reiterates a Buy on Apellis, signaling continued conviction in longer‑term commercial execution and pipeline upside — a supportive note for investors focused beyond the near term. Wells Fargo Buy Note
• Positive Sentiment: Stifel Nicolaus initiated/issued a Buy (or reiterated) view, adding another constructive Wall Street voice that could help anchor valuation if execution improves. Stifel Buy Note
• Neutral Sentiment: Analysts remain conflicted on Apellis — some highlight upside from Syfovre rollout and nephrology expansion while others emphasize near‑term sales risk and valuation — expect continued mixed research notes and volatile reactions to company updates. Analysts Conflicted
• Negative Sentiment: Apellis disclosed preliminary Q4 U.S. net product revenue of $190M; commentary pointed to weaker Syfovre sales and mixed Empaveli uptake — the primary near‑term catalyst behind a sharp weekly decline and investor concern about commercial momentum. Zacks Coverage on Revenue/Weak Sales
• Negative Sentiment: Major research houses (Cantor Fitzgerald, Needham) cut forecasts or turned more pessimistic, increasing downward pressure by lowering investor expectations and modelled revenues. Cantor Fitzgerald Note Needham Note
• Negative Sentiment: Significant insider selling: multiple senior execs (CEO, CFO, GC and others) sold shares on Jan. 13 — the volume of insider disposals can be read negatively by the market even though filings show they retain large stakes. SEC Form 4 (CEO Sale)
• Negative Sentiment: Options flow showed a >500% spike in put purchases (6,398 puts), indicating elevated hedging and bearish bets that can amplify short‑term volatility and downside pressure. Source: options flow report

Analyst Ratings Changes

Several research analysts recently weighed in on the company. TD Cowen dropped their price target on Apellis Pharmaceuticals from $50.00 to $45.00 and set a “buy” rating on the stock in a research report on Friday, October 31st. Wells Fargo & Company began coverage on shares of Apellis Pharmaceuticals in a report on Wednesday, October 15th. They set an “overweight” rating and a $32.00 price target for the company. Wolfe Research initiated coverage on shares of Apellis Pharmaceuticals in a research report on Thursday, November 6th. They set a “peer perform” rating on the stock. Wall Street Zen upgraded shares of Apellis Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. Finally, Mizuho decreased their target price on shares of Apellis Pharmaceuticals from $24.00 to $19.00 and set a “neutral” rating for the company in a research note on Monday, November 3rd. Eleven research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, Apellis Pharmaceuticals has an average rating of “Hold” and a consensus target price of $33.65.

Institutional Trading of Apellis Pharmaceuticals

Several large investors have recently made changes to their positions in APLS. Parallel Advisors LLC boosted its holdings in shares of Apellis Pharmaceuticals by 80.0% during the 2nd quarter. Parallel Advisors LLC now owns 1,924 shares of the company’s stock worth $33,000 after buying an additional 855 shares during the period. Jones Financial Companies Lllp raised its holdings in Apellis Pharmaceuticals by 206.8% in the 3rd quarter. Jones Financial Companies Lllp now owns 2,037 shares of the company’s stock worth $46,000 after acquiring an additional 1,373 shares during the period. Allworth Financial LP lifted its position in Apellis Pharmaceuticals by 64.1% during the 3rd quarter. Allworth Financial LP now owns 2,194 shares of the company’s stock worth $50,000 after acquiring an additional 857 shares during the last quarter. Osaic Holdings Inc. boosted its holdings in Apellis Pharmaceuticals by 141.2% during the second quarter. Osaic Holdings Inc. now owns 2,682 shares of the company’s stock valued at $47,000 after acquiring an additional 1,570 shares during the period. Finally, Quantbot Technologies LP bought a new stake in Apellis Pharmaceuticals during the third quarter valued at about $64,000. Institutional investors own 96.29% of the company’s stock.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, traded as NASDAQ:APLS, is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the complement cascade for the treatment of rare and debilitating diseases. The company’s research and development efforts center on modulating complement proteins to address a range of ophthalmologic, hematologic and renal conditions. Apellis leverages its proprietary compstatin technology platform to design targeted inhibitors intended to improve patient outcomes and quality of life.

The company’s lead marketed product, Syfovre (pegcetacoplan), is an intravitreal complement C3 inhibitor approved for geographic atrophy secondary to age-related macular degeneration, with ongoing investigations in other retinal disorders.